Bear mar­ket slows Pep­Gen's roll, caus­ing DMD-fo­cused biotech to price be­low range

A month af­ter Pep­Gen tran­si­tioned to a clin­i­cal-stage com­pa­ny with its Duchenne mus­cu­lar dy­s­tro­phy tri­al in Cana­da, the Boston biotech is de­but­ing on Wall Street …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER